Table 2. Patients, meningiomas, treatments and outcomes.
| Patients | 235 |
| Median age (range) | 58.6 years (13.7–86.5 years) |
| Male:Female (ratio) | 85:150 (1:1.8) |
| History of head or neck radiotherapy | 11 (5%) |
| Multiple meningiomas | 54 (23%) |
| Race | |
| Caucasian | 157 (67%) |
| Hispanic | 25 (11%) |
| Asian | 22 (9%) |
| Black | 12 (5%) |
| Other (not Hispanic/Latino) | 6 (3%) |
| Pacific islander | 5 (2%) |
| White; Hispanic/Latino | 2 (1%) |
| Meningiomas | 257 |
| World Health Organization (WHO) grade I | 128 (50%) |
| WHO grade II (atypical) | 104 (40%) |
| WHO grade III (anaplastic) | 25 (10%) |
| Primary:recurrent (ratio) | 189:68 (2.8:1) |
| Median size (range) | 33.4 cm3 (0.3–335.3 cm3) |
| Bone invasion | 88 (34%) |
| Brain invasion | 47 (18%) |
| Peri-meningioma edema | 150 (58%) |
| Location | |
| Anterior cranial fossa | 54 (21%) |
| Middle cranial fossa | 58 (23%) |
| Posterior cranial fossa | 34 (13%) |
| Midline | 118 (46%) |
| Convexity | 157 (61%) |
| Skull base | 109 (42%) |
| Treatment | |
| Extent of resection | |
| Gross total resection | 147 (57%) |
| Subtotal resection | 109 (42%) |
| Extent of resection unknown | 1 (0.4%) |
| Adjuvant radiotherapy | 61 (24%) |
| Outcomes | |
| Median follow-up (range) | 52 months (0–197 months) |
| Local failure | 92 (36%) |
| Median local freedom from progression (range) | 76 months (1.7–207 months) |
| Death | 60 (27%) |
| Median overall survival (range) | 80 months (0–191 months) |